Mesa Biotech Developing Molecular Point-of-Care (PCR) Diagnostic Test for Novel Coronavirus (COVID-19)

SAN DIEGO, March 4, 2020 /PRNewswire/ — Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed an affordable, sample-to-answer molecular testing platform designed for point-of-care (POC) infectious disease diagnosis, today announced the addition of the novel coronavirus (SARS-CoV-2) to its active influenza clinical trial in China. The […]

Click here to view original web page at